Search - tctmd.com

Displaying 201 - 220 of 238

Sort: Relevancy | Date

Presentation TCT 2017

Mortality and Stroke After PCI vs CABG In Left Main and 3VD: An Individual Patient Data Meta-analysis

Presenter: Dean J. Kereiakes, Spencer B. King III, A. Pieter Kappetein

October 30, 2017

Presentation TCT 2017

Influence of Diversity: Should Sex, Race, and Ethnicity Affect Revascularization Decisions? Does It?

Presenter: Dean J. Kereiakes, Spencer B. King III, Roxana Mehran

October 30, 2017

Presentation TCT 2017

Impact of Mandatory Stent Price Controls 2: My New Insights From Inside Industry

Presenter: Dean J. Kereiakes, Spencer B. King III, Ian T. Meredith

October 30, 2017

Presentation TCT 2017

Impact of Mandatory Stent Price Controls 1: Physician Perspectives

Presenter: Dean J. Kereiakes, Spencer B. King III, Upendra Kaul

October 30, 2017

Presentation TCT 2017

Impact of AUC and Public Reporting: Is PCI Now More Appropriate?

Presenter: Dean J. Kereiakes, Spencer B. King III, Michael A. Kutcher

October 30, 2017

Presentation TCT 2017

Metallic DES: What Can We Expect From New Drugs, Polymers, and Metals? Have We Reached the Limit of Iterative Development?

Presenter: Dean J. Kereiakes, Spencer B. King III, Elazer R. Edelman

October 30, 2017

Presentation TCT 2017

New Insights Into Neoatherosclerosis and Other Causes of Metallic Stent Thrombosis: Will the Most Dreaded Complication Always Be With Us?

Presenter: Dean J. Kereiakes, Spencer B. King III, Aloke V. Finn

October 30, 2017

Presentation TCT 2017

Very Late Stent Failures and Non-Stent Related Events: Insights Into Improving Event-Free Survival

Presenter: Dean J. Kereiakes, Spencer B. King III, Lorenz Raber

October 30, 2017

Presentation TCT 2017

Keynote Lecture: A Brief 40-Year History of PCI - How Far We've Come, How Far We Have to Go

Presenter: Dean J. Kereiakes, Spencer B. King III, Robert A. Byrne

October 30, 2017

Presentation TCT 2017

Drug-Coated Balloons in the Lower Extremity: Impact and Lessons Learned

Presenter: Michael Guiry, Julie Logan, Craig M. Walker

October 30, 2017

Presentation TCT 2017

Case Presentation: DCB in a De Novo Lesion

Presenter: Roxana Mehran, Bo Xu, Jun Jiang

October 29, 2017

Presentation TCT 2017

Current Practice and Perspectives on DCB in China

Presenter: Roxana Mehran, Bo Xu, YunDai Chen

October 29, 2017

Presentation TCT 2017

Case Presentation: Implantation of BRS With Imaging Follow-up

Presenter: Roxana Mehran, Bo Xu, Lei Song

October 29, 2017

Presentation TCT 2017

Clinical Trial Updates of BRS in China

Presenter: Roxana Mehran, Bo Xu, Kai Xu

October 29, 2017

News Industry News

TriReme Medical Reports Negative Late Lumen Loss At 24-Month Angiographic Follow-Up For Chocolate Heart™ Drug-Coated Coronary Balloon

June 22, 2017

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

Presentation TCT 2016

Novel DCB Coatings and Alternative Drugs: Are We Reaching the End of the Road?

Presenter: Fernando Alfonso, Juan F. Granada

November 01, 2016

Presentation TCT 2016

Methods and Technologies to Improve DCB Outcomes: Does the Data Support Their Use?

Presenter: Fernando Alfonso, Juan F. Granada, Azeem Latib

November 01, 2016

Presentation TCT 2016

DCB for De Novo Lesions: Clinical Applications and Technical Pitfalls

Presenter: Fernando Alfonso, Juan F. Granada, Bernardo Cortese

November 01, 2016

Presentation TCT 2016

DEBATE: DCB for In-Stent Restenosis: Does the Current Data Support Broad Adoption? Yes! The Data is Solid and DCB Should be the Treatment of Choice!

Presenter: Fernando Alfonso, Juan F. Granada, Bruno Scheller

November 01, 2016

Advertisement

Mortality and Stroke After PCI vs CABG In Left Main and 3VD: An Individual Patient Data Meta-analysis

Influence of Diversity: Should Sex, Race, and Ethnicity Affect Revascularization Decisions? Does It?

Impact of Mandatory Stent Price Controls 2: My New Insights From Inside Industry

Impact of Mandatory Stent Price Controls 1: Physician Perspectives

Impact of AUC and Public Reporting: Is PCI Now More Appropriate?

Metallic DES: What Can We Expect From New Drugs, Polymers, and Metals? Have We Reached the Limit of Iterative Development?

New Insights Into Neoatherosclerosis and Other Causes of Metallic Stent Thrombosis: Will the Most Dreaded Complication Always Be With Us?

Very Late Stent Failures and Non-Stent Related Events: Insights Into Improving Event-Free Survival

Keynote Lecture: A Brief 40-Year History of PCI - How Far We've Come, How Far We Have to Go

Drug-Coated Balloons in the Lower Extremity: Impact and Lessons Learned

Case Presentation: DCB in a De Novo Lesion

Current Practice and Perspectives on DCB in China

Case Presentation: Implantation of BRS With Imaging Follow-up

Clinical Trial Updates of BRS in China

TriReme Medical Reports Negative Late Lumen Loss At 24-Month Angiographic Follow-Up For Chocolate Heart™ Drug-Coated Coronary Balloon

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Novel DCB Coatings and Alternative Drugs: Are We Reaching the End of the Road?

Methods and Technologies to Improve DCB Outcomes: Does the Data Support Their Use?

DCB for De Novo Lesions: Clinical Applications and Technical Pitfalls

DEBATE: DCB for In-Stent Restenosis: Does the Current Data Support Broad Adoption? Yes! The Data is Solid and DCB Should be the Treatment of Choice!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content